# US 2013/0280328 A1 · Treatment of inflammatory bowel disease with 6-mercaptopurine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280328 A1
- Document ID: US20130280328A1
- Status: Published application
- Kind: A1
- Application number: 13/921,836
- Filed: 2013-06-19
- Published: 2013-10-24
- Earliest claimed: 2008-04-18
- Inventors: Vered Rosenberger; Brenda Kolatch; Linda Susan Marshall; Anna Hotovely-Salomon
- Web page: https://patentgrep.com/patent/US20130280328A1

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine and also result in very few undesirable side effects.

## Claims

### Claim at position 1

1-50. (canceled)

### Claim 51

A method of treating inflammatory bowel disease (IBD) in a patient comprising administering a delayed release pharmaceutical composition comprising 6-mercaptopurine (6-MP) once per day for less than 12 weeks wherein the dose of 6-MP administered is not adjusted based on the patient's weight.

### Claim 52 (depends on 51)

The method of claim 51, wherein the delayed release pharmaceutical composition comprises 40 to 80 mg of 6-MP.

### Claim 53 (depends on 51)

The method of claim 51, wherein the delayed release pharmaceutical composition comprises 60 to 80 mg of 6-MP.

### Claim 54 (depends on 51)

The method of claim 51, wherein the delayed release pharmaceutical composition comprises about 80 mg of 6-MP.

### Claim 55 (depends on 51)

The method of claim 51, wherein the IBD is Crohn's disease.

### Claim 56 (depends on 51)

The method of claim 51, wherein the IBD is ulcerative colitis.

### Claim 57 (depends on 55)

The method of claim 55, wherein the method induces remission in about 8 weeks.

### Claim 58 (depends on 55)

The method of claim 55, wherein the method results in improvement in Inflammatory Bowel Disease Questionnaire score.

### Claim 59 (depends on 55)

The method of claim 55, wherein the method results in reduced side effects compared to the treatment with 1-1.5 mg/kg of an immediate release formulation of 6-MR.

### Claim 60 (depends on 59)

The method of claim 59, wherein the reduced side effects include decreased elevation in liver enzymes, no reduction in white blood cell counts, or decreased weight loss.

### Claim 61 (depends on 55)

The method of claim 55, wherein the method results in similar decreased levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as compared to the treatment with 1-1.5 mg/kg of an immediate release formulation of 6-MP.

### Claim 62 (depends on 51)

The method of claim 51, wherein the method results in a decrease in interferon-γ levels.

### Claim 63 (depends on 51)

The method of claim 51, wherein the delayed release pharmaceutical composition comprising 6-MP is in the form of a tablet.

### Claim 64 (depends on 63)

The method of claim 63, wherein the delayed release pharmaceutical composition is enterically coated.

### Claim 65 (depends on 64)

The method of claim 64, wherein the enteric coating imparts a delay in the release in the 6-MP following oral administration such that release of 6-MP occurs after passage of the composition through the stomach.

### Claim 66 (depends on 65)

The method of claim 65, wherein the release of 6-MP occurs at least about 1 hour after passage of the composition through the stomach.

### Claim 67 (depends on 66)

The method of claim 66, wherein the release of 6-MP occurs at least about 2 hours after passage of the composition through the stomach.

### Claim 68 (depends on 67)

The method of claim 67, wherein the release of 6-MP occurs at least about 3 hours after passage of the composition through the stomach.

### Claim 69 (depends on 65)

The method claim 65, wherein the delayed release pharmaceutical composition provides release of the 6-MP in the ileum or distal small intestine.

### Claim 70 (depends on 69)

The method of claim 69, wherein the delayed release pharmaceutical composition provides release of the 6-MP in the terminal ileum.
